. Author manuscript; available in PMC: 2008 Oct 29.

Published in final edited form as: Cancer Causes Control. 2008 Mar 6;19(7):767–774. doi: 10.1007/s10552-008-9139-4

Table 2.

Association between statin use and prostate cancer risk

Statin use	No. of cases	Total person-years	Age-adjusted HR (95% CI)	Multivariable-adjusted HR (95% CI)^a
All men	2,532	578,885
Never	2,286	533,979	Referent	Referent
Ever	246	44,906	1.00 (0.87–1.14)	0.88 (0.76–1.02)
Hydrophobic only^b	160	32,611	0.87 (0.73–1.03)	0.79 (0.66–0.94)
Hydrophilic only^c	8	2,391	0.76 (0.38–1.53)	0.67 (0.33–1.34)
Duration of use among men with 5+ years of data^d	1,637	506,596
Never	1,405	470,324	Referent	Referent
All statin users
1–2.9 years	79	15,943	0.77 (0.62–0.97)	0.75 (0.59–0.95)
3–4.9 years	66	9,844	0.96 (0.75–1.23)	0.92 (0.71–1.19)
5+ years	87	10,485	1.11 (0.89–1.38)	1.06 (0.83–1.34)
Hydrophobic statin users^b
1–2.9 years	57	13,250	0.74 (0.58–0.95)	0.74 (0.57–0.95)
3–4.9 years	38	7,352	0.90 (0.67–1.20)	0.88 (0.65–1.19)
5+ years	17	5,426	0.82 (0.58–1.17)	0.81 (0.56–1.16)

HR = hazard ratio and CI = confidence interval

Multivariable-adjusted models include age, diabetes, hypercholesterolemia, other lipid lowering drug use, and NSAID use

Includes users of lovastatin, simvastatin, fluvastatin, atorvastatin, and cerivastatin

Includes users of pravastatin and rosuvastatin

p = 0.63 and p = 0.09 from linear trend tests for the effect of the duration of all statin use and duration of hydrophobic statin use on prostate cancer risk